GPX2 and neoplasm: CT-RadScore further correlated with predicted sensitivity to key agents (for example, paclitaxel, gefitinib and carboplatin) and was mechanistically linked to GPX2-driven DNA replication licensing programmes and impaired antitumour immune cycling.<h4>Conclusion</h4>CT-RadScore is a non-invasive, biologically anchored radiomic signature that captures TME immune phenotypes and tumour proliferative programmes.